Hanmi’s driving force for R&D is transparent governance.

Hanmi Pharmaceutical, which invests more than 10% of its annual revenue in R&D in creating ‘Innovation’ and ‘Value’, is achieving sustainable growth based on firm principles of ethics, compliance, and responsible management.

The 'Korean R&D' model, which leads from first generics to incrementally modified drugs, fixed-dose combinations, and innovative new drugs, demonstrates Hanmi's differentiated governance through a rational and transparent decision-making culture, independent and objective responsible management, and preemptive risk management capabilities. Hanmi will go beyond Korea and become a leading global healthcare company through governance trusted by all customers, shareholders, and consumers.